title: Metabotropic glutamate receptors (mGluRs) regulate noxious stimulus-induced glutamate release in the spinal cord dorsal horn of rats with neuropathic and inflammatory pain.
abstract: In rats with persistent pain, spinal group I metabotropic glutamate receptor (mGluR) activity has been shown to be pronociceptive, whereas spinal group II/III activity is anti-nociceptive. In brain, group I mGluR activity produces positive feedback effects on glutamate release, whereas group II/III activity produces negative feedback effects. It is unknown whether the nociceptive versus anti-nociceptive effects of spinal group I versus group II/III mGluR activity depend on differential regulation of spinal glutamate release. Here, we used behavioral nociceptive testing and in vivo microdialysis to assess the effect of intrathecal treatment with group I mGluR antagonists [cyclopropan[b] chromen-1a-carboxylate, (CPCCOEt), 2-methyl-6-(phenylethynyl) pyridine (MPEP)] or groups II [aminopyrrolidine-2R,4R-dicarboxylate (APDC)] and III [l-2-amino-4-phosphonobutyrate (l-AP4)] mGluR agonists or vehicle, on nociception and noxious stimulus-induced increases in glutamate release in the spinal cord dorsal horn of rats with a chronic constriction injury (CCI) of the sciatic nerve or hind paw injection of complete Freund's adjuvant (CFA). None of the treatments significantly influenced basal spinal glutamate concentrations in either CCI or CFA rats. In CCI rats, formalin-induced nociception and increases in spinal glutamate concentrations were significantly attenuated by pre-treatment with CPCCOEt, MPEP, APDC, or l-AP4. In CFA rats, capsaicin-induced increases in nociception and spinal glutamate concentrations were significantly attenuated by pre-treatment with CPCCOEt, MPEP, or APDC, but not l-AP4. This study demonstrates that group I antagonists and group II/III mGluR agonists attenuated the enhanced nociception and noxious stimulus-induced glutamate release in spinal cord dorsal horn of CCI and/or CFA rats in vivo, and suggests a possible mechanism for their anti-hyperalgesic effects.
authors.affiliation: Department of Anesthesia, McGill University, Montreal, Quebec, Canada H3G 1Y6.
authors.forename: Naresh
authors.initials: N
authors.lastname: Kumar
authors.forename: Andre
authors.initials: A
authors.lastname: Laferriere
authors.forename: Jonathan S C
authors.initials: JS
authors.lastname: Yu
authors.forename: Tanya
authors.initials: T
authors.lastname: Poon
authors.forename: Terence J
authors.initials: TJ
authors.lastname: Coderre
mesh_terms: D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism*; D007249:Inflammation / Q000378:metabolism; D008297:Male; D010146:Pain / Q000378:metabolism*; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000378:metabolism*; D020671:Posterior Horn Cells / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D020318:Rats, Long-Evans; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D018094:Receptors, Metabotropic Glutamate; D018698:Glutamic Acid; D002211:Capsaicin
references.citation: Neurosci Lett. 2004 May 6;361(1-3):220-4
references.pmid: 15135933
references.citation: Anesth Analg. 2007 Apr;104(4):936-43
references.pmid: 17377110
references.citation: Neurosci Lett. 2002 Jul 26;327(3):198-202
references.pmid: 12113911
references.citation: J Neurophysiol. 2004 Jan;91(1):13-24
references.pmid: 13679408
references.citation: Eur J Pharmacol. 2007 Sep 24;571(1):8-16
references.pmid: 17597604
references.citation: J Pharmacol Exp Ther. 2002 Jan;300(1):149-56
references.pmid: 11752110
references.citation: Neuroreport. 1994 Dec 30;6(1):209-13
references.pmid: 7703417
references.citation: Pain. 2005 May;115(1-2):37-49
references.pmid: 15836968
references.citation: Pain. 1988 Apr;33(1):87-107
references.pmid: 2837713
references.citation: Neuroscience. 1998 Jan;82(2):591-602
references.pmid: 9466463
references.citation: Neurosci Lett. 1999 Mar 5;262(2):101-4
references.pmid: 10203241
references.citation: Neuropharmacology. 2005 Mar;48(3):325-32
references.pmid: 15721164
references.citation: Pain. 2001 Oct;94(1):59-63
references.pmid: 11576745
references.citation: Mol Pain. 2009 Sep 02;5:50
references.pmid: 19725970
references.citation: Eur J Pharmacol. 1998 Apr 24;347(2-3):165-72
references.pmid: 9653877
references.citation: Neuroreport. 1998 Oct 5;9(14):3219-22
references.pmid: 9831454
references.citation: Neuropharmacology. 2007 Feb;52(2):253-62
references.pmid: 17113112
references.citation: Eur J Pain. 2000;4(1):111-3
references.pmid: 10833561
references.citation: Neurosci Res. 1999 Jul;34(2):73-8
references.pmid: 10498333
references.citation: Br J Pharmacol. 2002 Mar;135(5):1255-62
references.pmid: 11877334
references.citation: Neuroreport. 2000 Sep 28;11(14):3067-70
references.pmid: 11043525
references.citation: Pain. 1996 Oct;67(2-3):345-54
references.pmid: 8951928
references.citation: Neuroscience. 2000;100(2):393-406
references.pmid: 11008177
references.citation: Neuropharmacology. 2001 Sep;41(4):523-7
references.pmid: 11543773
references.citation: Neurosci Lett. 1997 Jul 4;229(3):161-4
references.pmid: 9237483
references.citation: Brain Res Bull. 2009 May 29;79(3-4):219-23
references.pmid: 19429193
references.citation: Neuroscience. 2001;105(4):957-69
references.pmid: 11530234
references.citation: J Comp Neurol. 2000 Jul 3;422(3):464-87
references.pmid: 10861520
references.citation: Pharmacol Biochem Behav. 2002 Sep;73(2):419-27
references.pmid: 12117597
references.citation: Eur J Neurosci. 1997 Jul;9(7):1350-5
references.pmid: 9240392
references.citation: Life Sci. 2004 May 14;74(26):3235-44
references.pmid: 15094324
references.citation: J Neurochem. 2003 Dec;87(5):1204-12
references.pmid: 14622100
references.citation: Pharmacol Biochem Behav. 2002 Sep;73(2):411-8
references.pmid: 12117596
references.citation: Eur J Pharmacol. 1998 Apr 24;347(2-3):189-95
references.pmid: 9653880
references.citation: J Neurochem. 2005 Aug;94(4):1131-9
references.pmid: 16092950
references.citation: Neurosci Lett. 1995 Dec 29;202(1-2):85-8
references.pmid: 8787837
references.citation: Exp Brain Res. 2003 May;150(2):194-200
references.pmid: 12669169
references.citation: Annu Rev Neurosci. 1994;17:31-108
references.pmid: 8210177
references.citation: J Pharmacol Exp Ther. 2005 Jan;312(1):120-6
references.pmid: 15375175
references.citation: Mol Pharmacol. 2002 May;61(5):989-96
references.pmid: 11961116
references.citation: Neuropharmacology. 1995 Jan;34(1):1-26
references.pmid: 7623957
references.citation: J Comp Neurol. 2007 Dec 1;505(4):412-23
references.pmid: 17912745
references.citation: J Neurochem. 2010 Jan;112(1):162-72
references.pmid: 19840219
references.citation: Brain Res. 2001 Sep 14;913(1):18-26
references.pmid: 11532243
references.citation: Neuroreport. 2000 Jun 5;11(8):1631-5
references.pmid: 10852214
references.citation: Eur J Neurosci. 2007 Jul;26(2):312-22
references.pmid: 17650109
references.citation: Neuroreport. 1997 Aug 18;8(12):2695-9
references.pmid: 9295103
references.citation: Eur J Pharmacol. 2004 Dec 15;506(2):107-18
references.pmid: 15588730
references.citation: Anesth Analg. 2003 Aug;97(2):520-525
references.pmid: 12873947
references.citation: Neurosci Lett. 1992 Oct 12;145(2):141-4
references.pmid: 1361220
references.citation: Neuroscience. 1996 Apr;71(4):949-76
references.pmid: 8684625
references.citation: Pain. 1993 Apr;53(1):81-88
references.pmid: 8316394
references.citation: Pain. 2008 Jul;137(1):112-124
references.pmid: 17900808
references.citation: J Comp Neurol. 2001 Feb 19;430(4):448-57
references.pmid: 11169479
references.citation: Neuroreport. 2000 Nov 9;11(16):3611-4
references.pmid: 11095529